These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32915656)

  • 21. Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery.
    Mahato S
    Med Chem; 2022; 18(8):847-858. PubMed ID: 35156586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gallium maltolate has
    Bernstein LR; Zhang L
    Antivir Chem Chemother; 2020; 28():2040206620983780. PubMed ID: 33353394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral drug discovery: preparing for the next pandemic.
    Adamson CS; Chibale K; Goss RJM; Jaspars M; Newman DJ; Dorrington RA
    Chem Soc Rev; 2021 Mar; 50(6):3647-3655. PubMed ID: 33524090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug repurposing: new strategies for addressing COVID-19 outbreak.
    Shende P; Khanolkar B; Gaud RS
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):689-706. PubMed ID: 33183102
    [No Abstract]   [Full Text] [Related]  

  • 31. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
    Tomazou M; Bourdakou MM; Minadakis G; Zachariou M; Oulas A; Karatzas E; Loizidou EM; Kakouri AC; Christodoulou CC; Savva K; Zanti M; Onisiforou A; Afxenti S; Richter J; Christodoulou CG; Kyprianou T; Kolios G; Dietis N; Spyrou GM
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34009288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.
    Kumar A; Loharch S; Kumar S; Ringe RP; Parkesh R
    Comput Struct Biotechnol J; 2021; 19():424-438. PubMed ID: 33391634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
    Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
    Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2.
    Chuong C; DuChane CM; Webb EM; Rai P; Marano JM; Bernier CM; Merola JS; Weger-Lucarelli J
    Viruses; 2021 May; 13(6):. PubMed ID: 34070524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metal Complexes as Antiviral Agents for SARS-CoV-2.
    Karges J; Cohen SM
    Chembiochem; 2021 Aug; 22(16):2600-2607. PubMed ID: 34002456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.
    Duran-Frigola M; Bertoni M; Blanco R; Martínez V; Pauls E; Alcalde V; Turon G; Villegas N; Fernández-Torras A; Pons C; Mateo L; Guitart-Pla O; Badia-I-Mompel P; Gimeno A; Soler N; Brun-Heath I; Zaragoza H; Aloy P
    J Chem Inf Model; 2020 Dec; 60(12):5730-5734. PubMed ID: 32672454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
    Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
    Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pocket guide on how to structure SARS-CoV-2 drugs and therapies.
    Littler DR; MacLachlan BJ; Watson GM; Vivian JP; Gully BS
    Biochem Soc Trans; 2020 Dec; 48(6):2625-2641. PubMed ID: 33258925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.